Arno Therapeutics Granted Exclusive License For Oncology Diagnostic Technique By University of Minnesota

Published: Mar 04, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

FLEMINGTON, N.J., March 4, 2014 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced that it has signed an exclusive, worldwide license agreement with the University of Minnesota for technology related to a gene expression signature derived from archived breast cancer tissue samples. This technique has the potential to identify progesterone-stimulated pathway activation and in turn, help identify patients who would most likely benefit from treatment with Arno's lead compound, onapristone, an anti-progestin therapeutic aimed at treatment of men's and women's cancers.

Help employers find you! Check out all the jobs and post your resume.

Back to news